New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:15 EDTLMNX, HOLX, AFFX, SIEGY, LIFE, BDX, ABT, RHHBY, ILMN, A, ENZEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Enzo Biochem (ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs (ABT), Affymetrix (AFFX), Agilent (A), Becton Dickinson (BDX), Gen-Probe, Hologic (HOLX), Illumina (ILMN), Life Technologies (LIFE), Luminex (LMNX), Roche (RHHBY), and Siemens (SIEGY), and their related entities. At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.
News For ENZ;ABT;AFFX;A;BDX;HOLX;ILMN;LIFE;LMNX;RHHBY;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 25, 2015
08:28 EDTAAgilent upgraded to Buy from Neutral at BTIG
Subscribe for More Information
07:18 EDTA, RHHBY, ILMNG Corp to hold annual meeting
Subscribe for More Information
06:14 EDTRHHBYPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
09:15 EDTSIEGYSiemens to supply turbines for fuel efficient power plant in Michigan
Subscribe for More Information
09:06 EDTRHHBYRoche receives orphan status for treatment of pemphigus vulgaris
The FDA granted Roche's Genentech unit orphan status for rituximab, its treatment of pemphigus vulgaris.
07:05 EDTRHHBYRoche and BioMed X enter collaboration agreement to develop sensor technology
Subscribe for More Information
February 23, 2015
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
15:09 EDTBDXBecton Dickinson management to meet with JPMorgan
Meetings to be held in New York on February 24 and in Atlanta on February 25 hosted by JPMorgan.
07:23 EDTRHHBYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTABTAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTRHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
09:59 EDTHOLXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
09:09 EDTRHHBY, A, ILMNLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
07:28 EDTHOLXHologic upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
06:35 EDTHOLXHologic upgraded to Buy from Hold at Canaccord
05:31 EDTRHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information
February 18, 2015
09:35 EDTILMNIllumina management to meet with Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use